Clinical Design and Objectives

This Phase 1/2 trial evaluates the safety, optimal dose, and preliminary efficacy of Selinofus (a selective inhibitor of nuclear export (SINE)) in combination with the standard chemotherapy temozolomide in patients with recurrent glioblastoma. The study explores tumor reduction compared with a placebo arm, commenced on March 20, 2023, and is currently enrolling. The primary endpoints are safety profile and maximum tolerated dose, while secondary endpoints include progression‑free survival (PFS) and overall survival (OS).

Differentiation from Existing Therapies

Current standard treatment for recurrent glioblastoma consists of temozolomide plus radiotherapy, which yields limited efficacy. Selinofus blocks the CRM1 protein, inhibiting nuclear export and thereby disrupting cancer cell growth and survival through a novel mechanism. Because this pathway is independent of conventional alkylating agents, synergistic effects are anticipated when combined.

Expected Benefits and Risks

If the combination therapy demonstrates tumor shrinkage and disease stabilization, it could offer a new therapeutic option for patients with recurrent glioblastoma. However, Selinofus has been associated with hematologic toxicity and gastrointestinal adverse events, making safety monitoring a critical focus. Positive outcomes would increase the likelihood of advancing to a pivotal Phase 3 expansion study.

Investment and Industry Implications

Although government‑led, this trial represents a critical step in assessing the commercial viability of Selinofus. Success would enable Selinofus to expand its pipeline in the neuro‑oncology space and secure a differentiated position relative to existing alkylator‑based therapies. This could reshape the competitive landscape of the brain‑tumor drug market and stimulate investment interest from emerging biotech firms and large pharmaceutical companies.